Hayek Kallen Investment Management Has $2.15 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Hayek Kallen Investment Management decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 41,607 shares of the company’s stock after selling 423 shares during the quarter. Novo Nordisk A/S comprises approximately 1.3% of Hayek Kallen Investment Management’s investment portfolio, making the stock its 29th largest holding. Hayek Kallen Investment Management’s holdings in Novo Nordisk A/S were worth $2,151,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Advisors Preferred LLC acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $26,000. Winthrop Partners WNY LLC acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at $28,000. Valeo Financial Advisors LLC grew its position in Novo Nordisk A/S by 510.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after purchasing an additional 526 shares during the period. Wealthcare Advisory Partners LLC grew its position in Novo Nordisk A/S by 75.6% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock valued at $44,000 after purchasing an additional 372 shares during the period. Finally, Mirova acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at $49,000. 7.36% of the stock is owned by institutional investors.

NYSE NVO traded up $1.50 during mid-day trading on Friday, hitting $57.87. The company’s stock had a trading volume of 1,768,123 shares, compared to its average volume of 1,410,802. The company’s 50 day simple moving average is $53.15 and its 200 day simple moving average is $50.60. Novo Nordisk A/S has a twelve month low of $43.12 and a twelve month high of $57.93. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $135.11 billion, a price-to-earnings ratio of 22.96, a PEG ratio of 2.28 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.02. Novo Nordisk A/S had a net margin of 32.44% and a return on equity of 75.48%. The business had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.55 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 2.45 EPS for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several analysts recently issued reports on the stock. Citigroup raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 17th. ValuEngine raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Jefferies Financial Group downgraded shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research report on Friday, August 30th. Zacks Investment Research raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price target for the company in a research report on Monday, July 15th. Finally, Bank of America lifted their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a research report on Friday, September 13th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $159.65.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Read More: Is the QQQ ETF safe?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Leave a Reply

Your email address will not be published. Required fields are marked *

*